Waldron Private Wealth LLC Purchases 15,770 Shares of Bristol-Myers Squibb (NYSE:BMY)

Waldron Private Wealth LLC boosted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 123.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 28,498 shares of the biopharmaceutical company’s stock after acquiring an additional 15,770 shares during the quarter. Waldron Private Wealth LLC’s holdings in Bristol-Myers Squibb were worth $1,612,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. Heck Capital Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at $188,000. TriaGen Wealth Management LLC bought a new position in Bristol-Myers Squibb in the fourth quarter worth approximately $207,000. Caprock Group LLC raised its position in Bristol-Myers Squibb by 29.3% during the 4th quarter. Caprock Group LLC now owns 78,433 shares of the biopharmaceutical company’s stock valued at $4,436,000 after purchasing an additional 17,796 shares in the last quarter. Hunter Associates Investment Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 2.8% in the 4th quarter. Hunter Associates Investment Management LLC now owns 18,379 shares of the biopharmaceutical company’s stock worth $1,039,000 after buying an additional 504 shares during the period. Finally, Oak Harvest Investment Services grew its position in shares of Bristol-Myers Squibb by 0.8% during the 4th quarter. Oak Harvest Investment Services now owns 105,597 shares of the biopharmaceutical company’s stock worth $5,973,000 after buying an additional 818 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

BMY has been the subject of several recent research reports. Wolfe Research initiated coverage on Bristol-Myers Squibb in a report on Friday, November 15th. They issued a “peer perform” rating for the company. Leerink Partners raised Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $55.00 to $73.00 in a research report on Tuesday, November 12th. Truist Financial increased their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Daiwa America upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 13th. Finally, Daiwa Capital Markets raised shares of Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a report on Wednesday, November 13th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $56.60.

Bristol-Myers Squibb Stock Performance

BMY opened at $58.86 on Friday. The firm has a fifty day moving average price of $57.60 and a 200 day moving average price of $53.06. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $61.10. The stock has a market cap of $119.38 billion, a P/E ratio of -16.40, a P/E/G ratio of 2.10 and a beta of 0.45. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.31. The business had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the prior year, the company posted $2.00 EPS. Equities research analysts anticipate that Bristol-Myers Squibb will post 0.92 earnings per share for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be paid a $0.62 dividend. The ex-dividend date of this dividend is Friday, January 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 4.21%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -69.08%.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the sale, the senior vice president now directly owns 11,760 shares in the company, valued at approximately $654,091.20. The trade was a 5.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.